Announcement
04 Jun 2024
In June 2024, US BARDA awarded USD 40 million to CyanVac LLC to support a Phase 2b clinical trial of their intranasal COVID-19 vaccine candidate.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
04 Jun 2024
Revocation date:
No revocation date
Updated: 04 Jun 2024
State aid, unspecified
In force
On 4 June 2024, the Biomedical Advanced Research and Development Authority (BARDA) provided USD 40 million in funding to CyanVac to plan and execute a Phase 2b clinical trial for their PIV-5 vectored ...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.